Overexpression of biliverdin reductase enhances resistance to chemotherapeutics
| Autor: | Urszula Florczyk, Jozef Dulak, Slawomir Golda, Agata Zieba, Jaroslaw Cisowski, Alicja Jozkowicz |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Cancer Research
Oxidoreductases Acting on CH-CH Group Donors Bilirubin Antineoplastic Agents Biology Serine chemistry.chemical_compound Mice Animals Transcription factor Protein kinase C Protein Kinase C Biliverdin Dose-Response Relationship Drug Kinase Biliverdin reductase Membrane Proteins Molecular biology Cell biology Oncology chemistry Drug Resistance Neoplasm Doxycycline NIH 3T3 Cells Signal transduction Cisplatin Heme Oxygenase-1 |
| Zdroj: | Cancer letters. 300(1) |
| ISSN: | 1872-7980 |
| Popis: | Biliverdin reductase (BVR) converts biliverdin to bilirubin. Additionally, acting as a transcription factor and possessing a capacity of a serine/threonine kinase, it may modulate signaling pathways. In order to gain better understanding of BVR functions, we used genetically modified line of mouse fibroblasts with reversible overexpression of BVR. Current study revealed that enhanced activity of BVR may protect cells in stressful conditions arising from anti-cancer drugs, cisplatin and doxorubicin, the effect most probably related to PKC α/β activity, as its inhibition reversed BVR action. Therefore activity of BVR may be of significance in tumors and may influence the effectiveness of therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect